FAIR VALUE DISCLOSURES (Details Textual) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended
	Jan. 31, 2016	Aug. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate			15.00%
Payments to Acquire Intangible Assets			$ 84,182	$ 4,500
Long-term Debt, Total			115,199		$ 113,427
Finite-Lived Intangible Assets, Gross			161,879		76,498
Accrued Royalties Assumed in Asset Purchase			1,199	0
Merck Sharp Dohme B.V [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate	10.00%
Finite-Lived Intangible Assets, Gross	$ 75,000
Finite-Lived Intangible Asset, Useful Life	10 years
Acquisition Costs Capitalized	$ 300
Fair Value, Inputs, Level 1 [Member]
Fair Value Inputs, Assets, Quantitative Information
Notes Payable, Fair Value Disclosure				$ 128,500
Marketing and Distribution Rights [Member]
Fair Value Inputs, Assets, Quantitative Information
Finite-Lived Intangible Assets, Gross		$ 1,000	$ 11,042		$ 1,000
Finite-Lived Intangible Asset, Useful Life		7 years	4 years 8 months 12 days
Marketing and Distribution Rights [Member] | H2 - Pharma, LLC [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate	10.00%
Payments to Acquire Intangible Assets	$ 8,800
Finite-Lived Intangible Assets, Gross	$ 10,000
Finite-Lived Intangible Asset, Useful Life	4 years
Acquisition Costs Capitalized	$ 42
Accrued Royalties Assumed in Asset Purchase	$ 1,200